CHPA pushes for DXM bill
This article was originally published in The Tan Sheet
Executive Summary
The Consumer Healthcare Products Association "already has begun an initiative to seek reintroduction" of the Dextromethorphan Distribution Act of 2006 in the next session of Congress since the Senate did not address the legislation before Congress adjourned Dec. 9. The bill, which passed the House by voice vote Dec. 6, would allow FDA to limit the distribution of bulk ingredient DXM to people or entities registered with the agency, and would make it more difficult for teens to abuse the drug (1"The Tan Sheet" Dec. 11, 2006, p. 11). "We are committed to educating and empowering parents to take responsibility and action by informing their children of the dangers of abusing both Rx and OTC medicines," CHPA President Linda Suydam states in the association's executive newsletter Dec. 15...
You may also be interested in...
Dextromethorphan Bulk-Sale Limit Clears House, But Stalls In Senate
House leadership made a lame duck priority of legislation to restrict sales and distribution of bulk forms of dextromethorphan (DXM), but HR 5280 did not get the same treatment in the Senate
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.